Zentiva Second Quarter 2024 Earnings: EPS: RON0.099 (vs RON0.043 in 2Q 2023)
Zentiva (BVB:SCD) Second Quarter 2024 Results
Key Financial Results
- Revenue: RON285.0m (up 30% from 2Q 2023).
- Net income: RON68.9m (up 132% from 2Q 2023).
- Profit margin: 24% (up from 14% in 2Q 2023). The increase in margin was driven by higher revenue.
- EPS: RON0.099 (up from RON0.043 in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Zentiva shares are down 1.8% from a week ago.
Balance Sheet Analysis
While earnings are important, another area to consider is the balance sheet. We've done some analysis and you can see our take on Zentiva's balance sheet.
Valuation is complex, but we're here to simplify it.
Discover if Zentiva might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About BVB:SCD
Zentiva
Engages in the production and marketing of preparations and medicines for human use in Romania and internationally.
Flawless balance sheet with solid track record.
